1. 2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies. (September 2015) Authors: Ma, W.W.; Chung, I.; Lang, I.; Csõszi, T.; Wenczl, M.W.; Cubillo, A.; Chen, J.; Wong, M.; Park, J.O.; Kim, J.S.; Rau, K.M.; Melichar, B.; Gallego, J.; Smakal, M.; Kim, J.; Belanger, B.; Bayever, E.; Adiwijaya, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗